Patent ID: 11899017
Assignee: BRISTOL-MYERS SQUIBB COMPANY
Field: Measurement (Instruments)
Classification: CPC G  A  C | IPC A  C  G

Claim 0:
1. A method of treating a subject having cancer, comprising administering an antibody that specifically binds PD-1 (anti-PD-1 antibody) or PD-L1 (anti-PD-L1 antibody) to a subject identified as having (a) a circulating central memory T Cells (TCM): circulating T effector memory cells (Teff) ratio that is similar to or higher than the TCM: Teff ratio in the top 90% of healthy subjects; or
both (i) a circulating CD4+ TCM: circulating CD4+ Teff ratio and (ii) a circulating CD8+ TCM: circulating CD8+ Teff ratio that are similar to or higher than those, respectively, in the top 90% of healthy subjects;
wherein the anti-PD-1 antibody or anti-PD-L1 antibody is only administered to the subject if more than or equal to 1% of tumor cells in the subject express PD-L1 and wherein the Teff cells are negative for CD45RA and CCR7.